TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
- Friday, April 8, 2022, 7:06
- Finance
- Add a comment
SYDNEY, April 8, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company’s investigational novel drug, EVT801, a selective…
About the Author
adminasapcorp has written 41552 stories on this site.